Alto Neuroscience, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-27.
Alto Neuroscience, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 27, 2025. The filing reports $50M sold. Its industry group is Pharmaceuticals. It names Amit Etkin (Executive Officer, Director), Michael Hanley (Executive Officer), Adam Savitz (Executive Officer) (SEC Form D, October 27, 2025).
Is this your company?
Sell to companies like Alto Neuroscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Alto Neuroscience, Inc.
Free to see. No signup.
More on the people and the money behind Alto Neuroscience, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in California, filed within 90 days of this one, largest first.
Get an email when Alto Neuroscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Alto Neuroscience, Inc. raises, hires or launches. No email unless you switch it on.
Watch Alto Neuroscience, Inc. →Get the full cited report on Alto Neuroscience, Inc.
What the filing shows about Alto Neuroscience, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Alto Neuroscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Alto Neuroscience, Inc.'s address as 650 Castro Street, Suite 450, Mountain View, CA 94041.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Alto Neuroscience, Inc. See pricing
Alto Neuroscience, Inc. is a registered filer with the SEC (CIK 1999480) and has filed since 2023-11-27. 5 filings are on record, the latest on 2025-10-27.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Alto Neuroscience, Inc.'s Form D of 2025-10-27 names Amit Etkin, Michael Hanley, Adam Savitz and 6 more as its officers, directors or promoters.
Its new offerings report $193.87M sold across 5 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
We leverage the biology of individuals’ brains to develop personalized and highly effective medicines, helping patients get better faster.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Amit Etkin is named as Executive Officer and Director on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Michael Hanley is named as Executive Officer on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Adam Savitz is named as Executive Officer on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Nicholas Smith is named as Executive Officer on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Gwill York is named as Director on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Christopher Cox is named as Director on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Andrew Dreyfus is named as Director on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Husseini Manji is named as Director on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
Raymond Sanchez is named as Director on the Form D that Alto Neuroscience, Inc. filed with the SEC on 27 October 2025, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2025-10-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Alto Neuroscience, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Alto Neuroscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alto Neuroscience, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Alto Neuroscience, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Alto Neuroscience, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (altoneuroscience.com).
Each opens in a new tab, filled in for Alto Neuroscience, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/alto-neuroscience-inc-form-d-25000001